Anti-Integrin alpha 4 antibody is a Mouse antibody of IgG class that binds to an Integrin alpha 4.
Figure 1 Binding of mAb ACT-1 to RMPI8866 cells.
RPMI8866 cells (0.5 x106) were incubated with 1 μg APC labeled ACT-1 (α4β7 specific antibody). Antibody binding was measured by flow cytometry and is presented as a histogram. Over 99% of the RPMI8866 cells expressed α4β7 integrin. Unstained cells (grey shading) and isotype control antibody (solid line) were used as controls.
Peachman, K. K., Karasavvas, N., Chenine, A. L., McLinden, R., Rerks-Ngarm, S., Jaranit, K., ... & Michael, N. L. (2015). Identification of new regions in HIV-1 gp120 variable 2 and 3 loops that bind to α4β7 integrin receptor. PLoS One, 10(12), e0143895.
Figure 2 Inhibition of binding of α4β7 integrin receptor to MAdCAM-1.
RMPI8866 cells were incubated with media only (solid circles) or with ACT-1 (0.5 μg/well; open circles, left panel) and then added to MAdCAM-1 (natural ligand of α4β7 integrin; 0.2 μg/well) coated plates. The plates were washed and 100 μl of media and 10 μl of AlamarBlue® dye were added to each well. Fluorescence was measured immediately after the addition of the dye (time 0) and then at 2 hours intervals for 8 hours. The percent inhibition at the 8 hour time point is shown.
Peachman, K. K., Karasavvas, N., Chenine, A. L., McLinden, R., Rerks-Ngarm, S., Jaranit, K., ... & Michael, N. L. (2015). Identification of new regions in HIV-1 gp120 variable 2 and 3 loops that bind to α4β7 integrin receptor. PLoS One, 10(12), e0143895.
Figure 3 Binding of α4β7 integrin receptor to cyclic and linear V2 peptides.
RMPI8866 cells were incubated with media (solid circles), ACT-1 (open circles) and then added to (B) linear (left panel), cyclic V2 peptides (TH023, MN, and acute C, second, third and right panels, respectively), or (C) cyclic V3 peptides (TH023, left panel, MN, middle panel, and acute C, right panel) coated plates respectively. The plates were washed and 100 μl of media and 10 μl of AlamarBlue® dye was added to each well. Fluorescence was measured immediately after the addition of the dye (time 0) and then at 2 hour intervals for 8 hours. The percent inhibition at the 8 hour time point is shown in each panel.
Peachman, K. K., Karasavvas, N., Chenine, A. L., McLinden, R., Rerks-Ngarm, S., Jaranit, K., ... & Michael, N. L. (2015). Identification of new regions in HIV-1 gp120 variable 2 and 3 loops that bind to α4β7 integrin receptor. PLoS One, 10(12), e0143895.
This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:
• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production
See more details about Hi-Affi™ recombinant antibody benefits.
Download resources about recombinant antibody development and antibody engineering to boost your research.
Select a product category from the dropdown menu below to view related products.
CAT | Product Name | Application | Type |
---|---|---|---|
TAB-135 | Anti-Human Integrin alpha 4 beta 7 Recombinant Antibody (Etrolizumab) | IF, IP, Neut, FuncS, ELISA, FC, ICC | IgG1 - kappa |
There are currently no Customer reviews or questions for PABX-122. Click the button above to contact us or submit your feedback about this product.
To accurately reference this product in your publication, please use the following citation information:
(Creative Biolabs Cat# PABX-122, RRID: AB_3111701)
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.